Iniparib
Product Specifications
Product Name Alternative
BSI-201; NSC-746045; IND-71677
UNSPSC Description
Iniparib (BSI-201) is an irreversible inhibitor of PARP1, used in the research of triple negative breast cancer.
Target Antigen
Influenza Virus; PARP
Type
Reference compound
Related Pathways
Anti-infection;Cell Cycle/DNA Damage;Epigenetics
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/BSI-201.html
Purity
99.82
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=CC=C(C([N+]([O-])=O)=C1)I)N
Molecular Weight
292.03
References & Citations
[1]Liu X, et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res. 2012 Jan 15;18(2):510-23.|[2]Yin S, et al. Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells. PLoS One. 2017 Aug 17;12(8):e0183578.|[3]Ma W, et al. Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein-Barr virus. Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6590-5.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-12015/Iniparib-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-12015/Iniparib-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
CAS Number
160003-66-7
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
